by | May 12, 2025 | Anastasaki, Corina, Gutmann, David
— Published Date: 5/13/2025
Value Proposition: A novel approach to repurposing FDA-approved anti-epileptic drugs to treat brain and nerve tumors associated with neurofibromatosis type I, offering a faster, cost-effective pathway to address an urgent unmet medical need.
Technology Description
Neuro…
by | Feb 23, 2022 | Cui, Jianmin
— Disease indication – Long QT Syndrome (resulting in ventricular arrhythmia, epilepsy, deafness)
Drug format – Small molecule
Drug class – Lead compounds are repurposed drugs
Research stage and preliminary data – Based on in silico screening of KCNQ, the researchers selecte…
by | Jan 11, 2022 | Imoukhuede, Princess
— Technology Description
Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…
by | Dec 8, 2020 | Christopher, Matthew, DiPersio, John, Ley, Timothy, Petti, Allegra, Rettig, Michael
— Technology Description
Researchers at Washington University in St. Louis have discovered that interferon-gamma treatment could potentially prevent relapse after hematopoietic stem cell transplantation (HCT) treatment by making the cancer cells more visible to the donor immune cells. This technolog…
by | Jul 22, 2020 | Gutmann, David
— This mouse strain was designed to harbor a specific NF1 patient germline NF1 gene mutation.